Related Experiment Video
Updated: May 3, 2026
08:01
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
1.6K
CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause
Xin-Feng Wang1, Yan-Hua Wu, Mao-Shui Wang
1Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, China E-mail : wangmaoshui@gmail.com, wys20739@126.com.
Asian Pacific Journal of Cancer Prevention : APJCP
|February 18, 2014
Summary
This study found that CA153 and CEA tumor biomarkers can help diagnose the cause of malignant pleural effusions. These biomarkers show promise for improving diagnosis and treatment, especially for unknown primary cancers.
Area of Science:
- Oncology
- Biomarker Discovery
- Pleural Medicine
Background:
- Accurate diagnosis of malignant pleural effusions (MPEs) is crucial for patient management, particularly when the primary cancer is unknown.
- Limited clinical biomarkers exist for predicting the etiology of MPEs.
- This study investigated the utility of five common tumor biomarkers in pleural fluid.
Purpose of the Study:
- To evaluate the effectiveness of five tumor biomarkers (CEA, AFP, CA125, CA153, and CA199) in predicting the cause of malignant pleural effusions.
- To determine the sensitivity and specificity of these biomarkers for different cancer types.
- To identify optimal biomarkers for diagnosing MPEs of various origins, including lung cancer, mesothelioma, and lymphoma/leukemia.
Main Methods:
- A retrospective study analyzing pleural fluid samples from patients with known MPEs.
- Comparison of tumor marker levels (CEA, AFP, CA125, CA153, CA199) across seven distinct neoplasia groups using Kruskal-Wallis and Mann-Whitney U tests.
- Receiver operator characteristic (ROC) curve analysis to assess the diagnostic performance (sensitivity, specificity, AUC) of individual biomarkers.
Main Results:
- Significant differences in pleural effusion levels of CEA, AFP, CA153, and CA199 were observed among the neoplasia groups (P<0.01).
- CA153 demonstrated high diagnostic accuracy for lung adenocarcinoma (AUC: 0.838), lung squamous cell carcinoma (AUC: 0.716), and small-cell lung cancer (AUC: 0.812).
- CEA was identified as the best biomarker for diagnosing mesothelioma (AUC: 0.726) and lymphoma/leukemia (AUC: 0.923).
Conclusions:
- CA153 and CEA are valuable biomarkers for diagnosing various causes of malignant pleural effusion.
- These biomarkers have the potential to enhance diagnostic accuracy and guide treatment decisions for MPEs, especially in cases of unknown primary tumors.
- Further clinical validation may lead to improved management strategies for patients with malignant pleural effusions.
Related Concept Videos
01:28Pleural Effusion II: Symptoms and Management
1.4K
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
1.4K
01:25Pleural Effusion I: Introduction
6.3K
Pleural effusion is an abnormal fluid accumulation in the pleural cavity, a narrow space between the lungs and the chest wall. It is not a disease per se but rather a symptom or indication of an underlying disease. In normal circumstances, this space contains a small amount of fluid (5 to 15 mL), a lubricant facilitating the non-frictional movement of the pleural surfaces.
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's...
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's...
6.3K
01:19Pericarditis II: Clinical Features and Diagnostic Tests
633
Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
633
01:30Pleural Disorders: Types and Brief Description
1.1K
The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
1.1K
01:26Endoscopic Studies II: Thoracocentesis
2.5K
Thoracentesis(Thoracocentesis), commonly known as pleural tap, is a medical procedure where a 22 gauge needle is inserted into the pleural space, the area between the lung and chest wall. This procedure is commonly performed to diagnose or treat various respiratory disorders.
Description
Excess pleural fluid or air may accumulate in some respiratory disorders in the thoracic cavity. To treat pleural effusion, a physician conducts thoracentesis by carefully piercing the chest wall and entering...
Description
Excess pleural fluid or air may accumulate in some respiratory disorders in the thoracic cavity. To treat pleural effusion, a physician conducts thoracentesis by carefully piercing the chest wall and entering...
2.5K
01:30Pneumonia III: Complications and Assessment
1.4K
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.4K